Infant Bacterial (Sweden) Performance
| IBT-B Stock | SEK 55.80 1.00 1.82% |
On a scale of 0 to 100, Infant Bacterial holds a performance score of 4. The company retains a Market Volatility (i.e., Beta) of -0.0314, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Infant Bacterial are expected to decrease at a much lower rate. During the bear market, Infant Bacterial is likely to outperform the market. Please check Infant Bacterial's coefficient of variation, jensen alpha, and the relationship between the downside deviation and standard deviation , to make a quick decision on whether Infant Bacterial's current trending patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Infant Bacterial Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Infant Bacterial unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 423.4 M | |
| Free Cash Flow | -55.6 M |
Infant |
Infant Bacterial Relative Risk vs. Return Landscape
If you would invest 4,880 in Infant Bacterial Therapeutics on January 12, 2025 and sell it today you would earn a total of 700.00 from holding Infant Bacterial Therapeutics or generate 14.34% return on investment over 90 days. Infant Bacterial Therapeutics is generating 0.3396% of daily returns and assumes 5.4281% volatility on return distribution over the 90 days horizon. Simply put, 48% of stocks are less volatile than Infant, and 94% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Infant Bacterial Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Infant Bacterial's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Infant Bacterial Therapeutics, and traders can use it to determine the average amount a Infant Bacterial's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0626
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IBT-B | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.43 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.34 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Infant Bacterial is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Infant Bacterial by adding it to a well-diversified portfolio.
Infant Bacterial Fundamentals Growth
Infant Stock prices reflect investors' perceptions of the future prospects and financial health of Infant Bacterial, and Infant Bacterial fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Infant Stock performance.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | 271.56 M | |||
| Shares Outstanding | 10.85 M | |||
| Price To Earning | (18.41) X | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 8,324 X | |||
| EBITDA | (43.76 M) | |||
| Cash And Equivalents | 386.75 M | |||
| Cash Per Share | 48.15 X | |||
| Book Value Per Share | 29.55 X | |||
| Cash Flow From Operations | (55.62 M) | |||
| Earnings Per Share | (5.76) X | |||
| Total Asset | 408.48 M | |||
About Infant Bacterial Performance
Assessing Infant Bacterial's fundamental ratios provides investors with valuable insights into Infant Bacterial's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Infant Bacterial is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Infant Bacterial Therapeutics AB , a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company was founded in 2013 and is based in Stockholm, Sweden. Infant Bacterial is traded on Stockholm Stock Exchange in Sweden.Things to note about Infant Bacterial performance evaluation
Checking the ongoing alerts about Infant Bacterial for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Infant Bacterial help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Infant Bacterial had very high historical volatility over the last 90 days | |
| Net Loss for the year was (44.99 M) with profit before overhead, payroll, taxes, and interest of 12 K. | |
| Infant Bacterial Therapeutics has accumulated about 386.75 M in cash with (55.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 48.15. |
- Analyzing Infant Bacterial's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Infant Bacterial's stock is overvalued or undervalued compared to its peers.
- Examining Infant Bacterial's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Infant Bacterial's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Infant Bacterial's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Infant Bacterial's stock. These opinions can provide insight into Infant Bacterial's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.